The Final Programme is available here!
Late abstract submission is open until August 31!
Follow us!
  
Spread the word with #EFMC_ISMC
|
| Sunday September 2, 2018 |
| 13:30 | Registration |
|
| Steklena Hall |
| 16:00 | Opening Ceremony |
Prof. Marko ANDERLUH
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
| Kocka Hall |
| 16:20 | Chair |
Prof. Marko ANDERLUH
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
| Kocka Hall |
| Zika Virus: An Old Virus with a New Face |
Prof. Tatjana AVSIC-ZUPANC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
| Kocka Hall |
| 16:50 | Chair |
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| Kocka Hall |
| It’s a Small-Molecule World: Medicinal Chemistry Challenges and Opportunities for the Next Decade |
Dr Bayard HUCK
(MERCK BIOPHARMA, Darmstadt, Germany) |
| Kocka Hall |
| 17:20 | Award Ceremony |
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| Kocka Hall |
| 17:40 | Chair |
Prof. Henk TIMMERMAN
(VU UNIVERSITY AMSTERDAM, Oegstgeest, The Netherlands) |
| Kocka Hall |
| NAUTA AWARD FOR PHARMACOCHEMISTRY
Tools and Drugs for Purine Targets - Important Players in Inflammation and Cancer |
Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany) |
| Kocka Hall |
| 18:25 | Chair |
Prof. Hans Ulrich STILZ
(NOVO NORDISK, Cambridge, United States) |
| Kocka Hall |
| Synthetic Glycoconjugate Vaccines against Bacterial Infections |
Prof. Peter H. SEEBERGER
(MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Berlin, Germany) |
| Kocka Hall |
| 19:10 | Welcome Reception |
|
| Steklena & Kupola Hall |
| 20:30 | End of the Day |
|
| Monday September 3, 2018 |
| 08:30 | Chair |
Dr Laurent PROVINS
(UCB, Braine-l'Alleud, Belgium) |
| Kocka Hall |
| UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY
How Best to Discover Bioactive Small Molecules? |
Prof. Adam NELSON
(UNIVERSITY OF LEEDS, Leeds, United Kingdom) |
| Kocka Hall |
| 09:15 | Chair |
Prof. Roberto DI SANTO
(SAPIENZA UNIVERSITY OF ROME, Rome, Italy) |
| Kocka Hall |
| The Therapeutic Challenge of the New Era: Developing and Making Available Life Changing Treatment to Patients with Rare Diseases |
Dr Diego ARDIGO
(CHIESI GROUP, PARMA, Italy) |
| Kocka Hall |
| 10:00 | Exhibition & Coffee |
|
| Steklena & Kupola Hall |
Session 1 'Technologies'
Artificial Intelligence Applications in Medicinal Chemistry | Session 2 'Therapeutic Areas'
Immuno-Oncology: Novel Therapeutic Opportunities | Session 3 'Chemical Biology'
Glycans in Medicinal Chemistry: Carbohydrate-Based Vaccines
(EuChemS Session) |
| Marmorna Hall 1 | Kocka Hall | Marmorna Hall 2 |
| 10:30 | Session Chair |
Dr Jonas BOSTRÖM
(ASTRAZENECA, Mölndal, Sweden) |
|
| 10:30 | Session Chair |
Dr Luc VAN HIJFTE
(MERCACHEMSYNCOM, Nijmegen, The Netherlands) |
|
| 10:30 | Session Chair |
Dr Sonsoles MARTIN-SANTAMARIA
(CIB-CSIC, Madrid, Spain) |
|
| 10:35 | Artificial Intelligence. Not Just Another Name for in Silico Design |
Dr David E. LEAHY
(THE DISCOVERY BUS LTD, Macclesfield, United Kingdom) |
|
| 10:35 | Small Molecule Immune Checkpoint Antagonists for Cancer Therapy |
Dr Murali RAMACHANDRA
(AURIGENE DISCOVERY TECHNOLOGIES LTD, Bangalore, India) |
|
| 10:35 | Breaking the Limits in Analyzing Carbohydrate Recognition by NMR |
Dr Jesus JIMENEZ-BARBERO
(CIC BIOGUNE, Derio, Spain) |
|
| 11:15 | Re-Energising Small Molecule Drug Discovery
|
Dr Willem VAN HOORN
(EXSCIENTIA, Dundee, United Kingdom) |
|
| 11:15 | Tankyrase Inhibitor Development: Evidence for Potential in Cancer Immune Therapy |
Prof. Stefan KRAUSS
(UNIVERSITY OF OSLO, Oslo, Norway) |
|
| 11:15 | Targeting of Cancer Specific Glycopeptide Epitopes |
Prof. Hans WANDALL
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark) |
|
| 11:35 | Computer-Aided Synthesis Planning |
Dr Marwin SEGLER
(BENEVOLENTAI, Cambridge, United Kingdom) |
|
| 11:35 | Small Molecules Inhibiting PD1-PDL1 Immune Checkpoint |
Dr Shabnam SHAABANI
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands) |
|
| 11:35 | A Multidisciplinary Strategy to Synthetic Carbohydrate-Based Conjugates for Vaccination against Shigella: from Concept to First-in-Human Study |
Dr Laurence MULARD
(PASTEUR INSTITUTE, Paris, France) |
|
| 11:55 | Potency and Patents, New Arenas for Matched Molecular Pair Analysis in the AI World |
Dr Al DOSSETTER
(MEDCHEMICA LIMITED, Macclesfield, United Kingdom) |
|
| 11:55 | New Small-Molecule Immune Checkpoint Inhibitors: A Step Forward in Cancer Immunotherapy |
Ms Ana Rita DE CARVALHO ACURCIO
(UNIVERSITY OF LISBON, Lisbon, Portugal) |
|
| 11:55 | Glycoside Antagonists of Bacterial Lectins: New Treatment Options for Recurrent and Antibiotic Resistant UTI |
Prof. James JANETKA
(WASHINGTON UNIVERSITY IN SAINT LOUIS, Saint Louis, United States) |
|
|
| 12:15 | Exhibition & Lunch |
|
| Steklena & Kupola Hall |
Session 4 'Technologies'
Timing is Everything: Target Binding Kinetics and Pharmacokinetics | Session 5 'Therapeutic Areas'
Life Science at the Interface of Agro and Pharma | Session 6 'Chemical Biology'
Recent Advances in Targeted Protein Degradation |
| Marmorna Hall 1 | Kocka Hall | Marmorna Hall 2 |
| 13:15 | Session Chair |
Prof. Ad P. IJZERMAN
(LEIDEN UNIVERSITY, Leiden, The Netherlands) |
|
| 13:15 | Session Chair |
Dr Franz VON NUSSBAUM
(BAYER AG, Berlin, Germany) |
|
| 13:15 | Session Chair |
Dr Gregory HOLLINGWORTH
(NOVARTIS PHARMA AG, Basel, Switzerland) |
|
| 13:20 | "Micro-Pharmacokinetics”: How Local Drug Concentration Influences Observed Binding Kinetics |
Prof. Steven CHARLTON
(UNIVERSITY OF NOTTINGHAM, Nottingham, United Kingdom) |
|
| 13:20 | A New Target in Fungal Protein Biosynthesis: Shared Learnings for AgChem and MedChem |
Dr Franz VON NUSSBAUM
(BAYER AG, Berlin, Germany) |
|
| 13:20 | Recent Advances in Bifunctional Degrader Molecules (e.g. SNIPER) for Targeted Protein Degradation via the Ubiquitin Proteasome System; Status and Outlook |
Dr Mikihiko NAITO
(NATIONAL INSTITUTE OF HEALTH SCIENCES, Tokyo, Japan) |
|
| 14:00 | Allosteric Modulation of the mGlu2 Receptor: from Structure-Kinetic Relationships to in vivo Efficacy
(2017 MedChemComm Emerging Investigator Lectureship) |
Prof. Laura HEITMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands) |
|
| 14:00 | Natural Products as Leads in Agrochemistry |
Dr Joachim RHEINHEIMER
(BASF, Ludwigshafen am Rhein, Germany) |
|
| 14:00 | Targeting 'Undruggable' Transcription and Translation Factors for Degradation with Low Molecular Weight Cereblon Modulators |
Dr Philip CHAMBERLAIN
(CELGENE, San Diego, United States) |
|
| 14:20 | Target Binding Kinetics and its Relevance in the in vivo Context |
Dr Liesbeth DE LANGE
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands) |
|
| 14:20 | Synthesis and Fungicidal Activity of a New Family of Oxysterol Binding Protein Inhibitors |
Dr Laura QUARANTA
(SYNGENTA AG, Basel, Switzerland) |
|
| 14:20 | The Zinc-Degrome |
Dr Nicolas THOMÄ
(FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
|
| 14:40 | Large-Scale Analysis of Kinase Inhibitors' Target Binding Kinetics and its Implications for Drug Discovery |
Ms Victoria GEORGI
(BAYER AG, Berlin, Germany) |
|
| 14:40 | Targeting Non Essential Bacterial Targets as a Novel Route to Counteract Bacterial Resistance |
Prof. Gabriele COSTANTINO
(UNIVERSITY OF PARMA, Parma, Italy) |
|
| 14:40 | Drugging the Fbw7 E3 Ligase with a Combined Computational and Biophysical Approach |
Dr Carles GALDEANO
(UNIVERSITY OF BARCELONA, Barcelona, Spain) |
|
|
| 15:00 | Exhibition & Coffee |
|
| Steklena & Kupola Hall |
Session 7
First Time Disclosures |
| Kocka Hall |
| 15:30 | Session Chair |
Dr Emmanuel PINARD
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
|
| 15:35 | Discovery of RG7916, a Selective SMN2 Splicing Modifier for the Treatment of Spinal Muscular Atrophy |
Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel , Switzerland) |
|
| 16:05 | Discovery of LOU064, a Covalent BTK Inhibitor with Best in Class Selectivity |
Dr Robert PULZ
(NOVARTIS PHARMA, Basel, Switzerland) |
|
| 16:35 | Discovery of a Novel Oral NO- and Heme-Independent sGC Activator BAY 1101042 |
Dr Michael G. HAHN
(BAYER HEALTHCARE, Wuppertal, Germany) |
|
| 17:05 | First Time Disclosure of BI 409306, a First in Class PDE9 Inhibitor for the Treatment of CNS Diseases |
Dr Riccardo GIOVANNINI
(BOEHRINGER INGELHEIM, Biberach, Germany) |
|
|
| 17:35 | Poster Session 1 (even numbers) & Networking |
|
| Steklena & Kupola Hall |
| 19:30 | End of the Day |
|
| Tuesday September 4, 2018 |
| 08:30 | Chair |
Dr Josep Jr. PROUS
(PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, Barcelona, Spain) |
| Kocka Hall |
| PROUS INSTITUTE-OVERTON AND MEYER AWARD
FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
Activity-Based Proteomics - Protein and Ligand Discovery on a Global Scale |
Prof. Benjamin CRAVATT
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States) |
| Kocka Hall |
| 09:15 | Chair |
Dr Phil JONES
(BIOASCENT, Glasgow, United Kingdom) |
| Kocka Hall |
| Sugars & Proteins: Glycomimetics to Target Infectious Disease |
Prof. Benjamin DAVIS
(OXFORD UNIVERSITY, Oxford, United Kingdom) |
| Kocka Hall |
| 10:00 | Exhibition & Coffee |
|
| Steklena & Kupola Hall |
Session 8 'Technologies'
New Chemical Modalities in Medicinal Chemistry | Session 9 'Therapeutic Areas'
Targeting Aggregated Proteins in Neurodegenerative Diseases with Small Molecules | Sessions 10 'Chemical Biology'
Targeting the STING Pathway (Stimulator of Interferon Genes) |
| Marmorna Hall 1 | Kocka Hall | Marmorna Hall 2 |
| 10:30 | Session Chair |
Dr Eric VALEUR
(ASTRAZENECA, IMED BIOTECH UNIT, Cambridge, United States) |
|
| 10:30 | Session Chair |
Dr Laurent PROVINS
(UCB, Braine-l'Alleud, Belgium) |
|
| 10:30 | Session Chair |
Dr Thorsten OOST
(BOEHRINGER INGELHEIM, Biberach, Germany) |
|
| 10:35 | New Modalities for Complex and Unprecedented Biological Targets |
Dr Eric VALEUR
(ASTRAZENECA, IMED BIOTECH UNIT, Cambridge, United States) |
|
| 10:35 | Understanding Aggregation Inhibition of Alpha-Synuclein and Tau by Small Molecules |
Prof. Markus ZWECKSTETTER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany) |
|
| 10:35 | Intracellular DNA Sensing in Health and Disease |
Prof. Andrea ABLASSER
(EPFL, Lausanne, Switzerland) |
|
| 11:15 | Cell Permeability with Beyond ‘Rule of 5’ Modalities – Do We Understand How This Works? |
Dr Nick TERRETT
(MERCK SHARP & DOHME RESEARCH GMBH (MSD), Kriens, Switzerland) |
|
| 11:15 | Discovery of Peptidomimetics Targeting Protein-Protein Interactions of Alpha-Synuclein |
Dr Wolfgang WRASIDLO
(UNIVERSITY OF CALIFORNIA SAN DIEGO, La Jolla, United States) |
|
| 11:15 | Modification of Cyclic Dinucleotides to Enhance Modulation of the Innate Immune Response |
Dr Diane COE
(GLAXOSMITHKLINE, Stevenage, United Kingdom) |
|
| 11:35 | Novel Hybrid Macrocyclic Modalities for Structure-Based Protein Mimetics |
Dr Stéphanie GUERET
(ASTRAZENECA-MAX PLANCK INSTITUTE SATELLITE UNIT, Mölndal, Sweden) |
|
| 11:35 | Targeting the Monomeric Intrinsically Disordered Structural State of Tau and Alpha-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Alzheimer's and Parkinson’s Disease |
Dr Gergely TOTH
(CANTABIO PHARMACEUTICALS INC., Sunnyvale, United States) |
|
| 11:35 | Use of Cyclic Dinucleotides (CDNs) to Induce Stimulator of Interferon Genes (STING)-Dependent Antitumor Immunity |
Dr Cedric BOULARAN
(INVIVOGEN, Toulouse, France) |
|
| 11:55 | Small-Molecule Stabilization of Protein-Protein Interactions by Natural Products, Supramolecular Ligands, Fragments and Macrocycles |
Dr Christian OTTMANN
(EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands) |
|
| 11:55 | Brain-Penetrant Autophagy Modulators for Treating Neurodegenerative Diseases |
Dr Steve ANDREWS
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom) |
|
| 11:55 | In vivo Anti-Viral and -Tumor Effect Of 3’3’-cAIMP STING Activation |
Dr Martin K. THOMSEN
(AARHUS UNIVERSITY, Aarhus C, Denmark) |
|
|
| 12:15 | Exhibition & Lunch |
|
| Steklena & Kupola Hall |
| 12:15 | Chemical Computing Group Workshop
MOEsaic: The application of Matched Molecular Pair Analysis to SAR Exploration
|
|
| Povodni Mož Hall 3 |
| Flash Posters 1 | Flash Posters 2
| Flash Posters 3 |
| Marmorna Hall 1 | Kocka Hall | Marmorna Hall 2 |
| Chair |
Prof. Lucija PETERLIN MASIC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
| 13:15 | Opportunity for 10 young scientists to present a summary of their poster
Discover the presenters here |
|
|
| Chair |
Dr Ziga JAKOPIN
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
| 13:15 | Opportunity for 10 young scientists to present a summary of their poster
Discover the presenters here |
|
|
| Chair |
Prof. Tihomir TOMASIC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
| 13:15 | Opportunity for 10 young scientists to present a summary of their poster
Discover the presenters here |
|
|
|
Session 11 'Technologies'
Expanding Medicinal Chemists’ Synthetic Toolbox | Session 12 'Therapeutic Areas'
Breakthroughs in Polypharmacology Towards Neurological Disorders
(ACS Session) | Session 13 'Chemical Biology'
Chemical Biology Approaches to Target Identification |
| Marmorna Hall 1 | Kocka Hall | Marmorna Hall 2 |
| 13:45 | Session Chair |
Prof. György KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary) |
|
| 13:45 | Session Chair |
Prof. Maria Laura BOLOGNESI
(UNIVERSITY OF BOLOGNA, Bologna, Italy) |
|
| 13:45 | Session Chair |
Prof. Herbert WALDMANN
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany) |
|
| 13:50 | Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis |
Prof. Karl GADEMANN
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland) |
|
| 13:50 | Multi-Functional Treatments for Multi-Factorial Neurodegenerative Disorders: the Challenge of Alzheimer's Disease |
Dr Mark J. MILLAN
(INSTITUT DE RECHERCHES SERVIER, Croissy-sur-Seine, France) |
|
| 13:50 | Activity-Based Glycosidase Profiling in Biomedicine and Biotechnology |
Prof. Hermen OVERKLEEFT
(LEIDEN UNIVERSITY, Leiden, The Netherlands) |
|
| 14:30 | Stuck in a Rut with Old Chemistry |
Dr Jonas BOSTRÖM
(ASTRAZENECA, Mölndal, Sweden) |
|
| 14:30 | Beyond Single-Target Activities: Using Polypharmacology and Systems Readouts for Compound Selection and Mode-of-Action Analysis |
Prof. Andreas BENDER
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom) |
|
| 14:30 | An Iron Hand over Cancer Stem Cells |
Dr Raphaël RODRIGUEZ
(INSTITUT CURIE, Paris, France) |
|
| 14:50 | New Chemical Libraries in Exploration of Chemical Space |
Prof. Jurij SVETE
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
|
| 14:50 | In silico Polypolpharmacology |
Dr Giovanni BOTTEGONI
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom) |
|
| 14:50 | Charting the Structure-Resistance Landscape of Novel Antibiotics |
Mr Tamas REVESZ
(BIOLOGICAL RESEARCH CENTRE, HUNGARIAN ACADEMY OF SCIENCES, Szeged, Hungary) |
|
| 15:10 | Integrated System for the Expedited Generation and Characterization of Drug-Like Libraries for Hit-to-Lead Explorations |
Prof. Antimo GIOIELLO
(UNIVERSITY OF PERUGIA, Perugia, Italy) |
|
| 15:10 | Metabotropic Glutamate Receptor Type 2 Positive Allosteric Modulators (mGlu2 Receptor PAMS) as a Transformational Epilepsy Treatment |
Dr Jose CID
(JANSSEN R&D, Toledo, Spain) |
|
| 15:10 | Buruli Ulcer and the mTOR Pathway: Total Synthesis, Structure-Activity and Target Elucidation Studies of Mycolactones |
Prof. Matthias GEHRINGER
(UNIVERSITY OF TUEBINGEN, Tuebingen, Germany) |
|
|
| 15:30 | Exhibition & Coffee |
|
| Steklena & Kupola Hall |
| Flash Posters 4 | Flash Posters 5 | Flash Posters 6 |
| Marmorna Hall 1 | Kocka Hall | Marmorna Hall 2 |
| Chair |
Prof. Danijel KIKELJ
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
| 16:00 | Opportunity for 15 young scientists to present a summary of their poster
Discover the presenters here |
|
|
| Chair |
Prof. Jurij SVETE
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
| 16:00 | Opportunity for 15 young scientists to present a summary of their poster
Discover the presenters here |
|
|
| Chair |
Prof. Janez ILAS
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
| 16:00 | Opportunity for 15 young scientists to present a summary of their poster
Discover the presenters here |
|
|
|
| 16:45 | Poster Session 2 (odd numbers) & Networking |
|
| Steklena & Kupola Hall |
| 18:45 | End of Poster Session |
|
| 20:00 | Concert |
|
| Cankarjem dom - Linhart Hall | | Wednesday September 5, 2018 |
| 08:30 | Chair |
Dr Jürgen MACK
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany) |
| Kocka Hall |
| Development of Non-Nucleosidic Compounds against DNA Viruses of the Herpes Group. The Era After Nucleosides: Letermovir and Pritelivir
|
Dr Helga RÜBSAMEN-SCHAEFF
(AICURIS GMBH & CO. KG, Wuppertal, Germany) |
| Kocka Hall |
| 09:15 | EFMC Prize Ceremony |
Dr Matthew TOZER (CONSULTANT, Bognor Regis, United Kingdom)
Prof. Rui MOREIRA (UNIVERSITY OF LISBON, Lisbon, Portugal) |
| Kocka Hall |
| 09:20 | EFMC Prize for a Young Medicinal Chemist in Industry
The Challenges of Restoring Programmed Cell Death Through MCL1 Inhibition |
Dr Marton CSEKEI
(SERVIER RESEARCH INSTITUTE OF MEDICINAL CHEMISTRY, Budapest, Hungary) |
| Kocka Hall |
| 09:40 | EFMC Prize for a Young Medicinal Chemist in Academia
Carbohydrate-binding Proteins as Targets for Anti-Infectives and Diagnostics: ESKAPE pathogen Pseudomonas aeruginosa and its Lectins |
Dr Alexander TITZ
(HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL SCIENCES, Saarbrücken, Germany) |
| Kocka Hall |
| 10:00 | Exhibition & Coffee |
|
| Steklena & Kupola Hall |
Session 14 'Technologies'
Development of New Synthetic Methodologies for Drug Discovery
(CPA Session) | Session 15 'Therapeutic Areas'
Upcoming Treatments for NASH and Other Fibrotic Diseases | Session 16 'Chemical Biology'
Recent Developments in Kinase Inhibitors |
| Marmorna Hall 1 | Kocka Hall | Marmorna Hall 2 |
| 10:30 | Session Chair |
Dr Ming-Qiang ZHANG
(AMGEN, Shanghai City, China) |
|
| 10:30 | Session Chair |
Prof. Roberto PELLICCIARI
(TES PHARMA SRL, Corciano, Italy) |
|
| 10:30 | Session chair |
Prof. Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany) |
|
| 10:35 | Tricyclic Peptides via Templated Tandem CLIPS/CUAAC Cyclizations |
Prof. Peter TIMMERMAN
(PEPSCAN THERAPEUTICS, Lelystad, The Netherlands) |
|
| 10:35 | Obeticholic Acid, Leading in the NASH Race. History and Perspectives |
Prof. Roberto PELLICCIARI
(TES PHARMA SRL, Corciano, Italy) |
|
| 10:35 | EGFR Triple Mutant L858R_T790M_ C797S Recent Set-Backs and New Hope in Fighting Mutant Non-Small Cell Lung Cancer |
Prof. Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany) |
|
| 11:15 | Asymmetric Synthesis of Statin API as the Hypolipidemic Agents: The Evolution from the Chemical Kinetic Resolution to the Asymmetric Catalytic Technology (An Odessy) |
Prof. Fener CHEN
(FUDAN UNIVERSITY, Shanghai Shi, China) |
|
| 11:15 | Discovery of LJN452 (Tropifexor), a Highly Potent, Non-Bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and NASH |
Dr David TULLY
(NOVARTIS, Emeryville, United States) |
|
| 11:15 | Design and Rationale for Exquisite Selectivity of Preclinical and Clinical Kinase Inhibitors |
Dr Laurent SCHIO
(SANOFI, Vitry sur Seine, France) |
|
| 11:35 | Practical Asymmetric Hydrogenation |
Prof. Xumu ZHANG
(SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY, Guangdong, China) |
|
| 11:35 | The First Class of Orally Available Mono-Saccharide Galectin-3 Inhibitors for Treatment of Fibrosis (NASH) and Cancer |
Dr Fredrik ZETTERBERG
(GALECTO BIOTECH, Gothenburg, Sweden) |
|
| 11:35 | Chemical Probes for New Therapeutic Concept Discovery |
Dr Peter ETTMAYER
(BOEHRINGER-INGELHEIM, Vienna, Austria) |
|
| 11:55 | Synthesis of MedChem-Relevant Gem-Difluorocycloalkane Building Blocks |
Prof. Dmytro VOLOCHNYUK
(ENAMINE LTD, Kyiv, Ukraine) |
|
| 11:55 | Development of Small-Molecule Inhibitors of Adipose Triglyceride Lipase (ATGL) |
Ms Anna MIGGLAUTSCH
(TU GRAZ, Graz, Austria) |
|
| 11:55 | Discovery of the TYK2 Selective Inhibitor PF-6826647 for the Treatment of Crohn’s Disease, and Other Autoimmune Conditions |
Dr Brian GERSTENBERGER
(PFIZER, Cambridge, United States) |
|
|
| 12:15 | Exhibition & Lunch |
|
| Steklena & Kupola Hall |
| 12:15 | Schrödinger Workshop
Data Driven Drug Design – Using LiveDesign |
|
| Povodni Mož Hall 3 |
Session 17
Emerging Topics | Session 18 'Therapeutic Areas'
Addressing Infectious Diseases in the Developing Countries
(AFMC Session) | Session 19 'Chemical Biology'
The Sphingosine-1-Phosphate Axis: Therapeutic Potential in Inflammation, Cancer, and More
(ACS Session) |
| Kocka Hall | Marmorna Hall 2 |
| 13:15 | Session Chair |
Prof. Gabriele COSTANTINO
(UNIVERSITY OF PARMA, Parma, Italy) |
|
| 13:15 | Session Chair |
Dr Renate GRIFFITH
(UNIVERSITY OF NEW SOUTH WALES, UNSW Sydney, Australia) |
|
| 13:15 | Session Chair |
Dr Tony LEE
(GILEAD SCIENCES, Seattle, United States) |
|
| 13:20 | Development of Potent, Selective, CNS Penetrant Small Molecule Inhibitors of Notum to Potentiate Wnt Signaling for the Maintainance of Synaptic Function in Alzheimer’s Disease |
Prof. Paul FISH
(ARUK UCL DRUG DISCOVERY INSTITUTE, London, United Kingdom) |
|
| 13:20 | All Bugs are Shallow: Open Source Drug Discovery |
Prof. Matthew TODD
(UNIVERSITY COLLEGE LONDON, London, United Kingdom) |
|
| 13:20 | Unravelling the Mysteries of the Sphinx: Novel Targets and Small-Molecule Therapeutics from the Sphingolipid Synthesis and Signaling Pathway |
Prof. Bernard FLYNN
(MONASH UNIVERSITY, Parkville, Australia) |
|
| 13:40 | Synthetic Small-Molecule RNA Ligands: Scope and Therapeutic Applications |
Dr Maria DUCA
(UNIVERSITÉ CÔTE D'AZUR, Nice, France) |
|
| 14:00 | Towards the Development of Novel Inhibitors for Chikungunya Virus Infection: Approaches in Structure-Activity-Metabolism Relationship (SAMR) Studies |
Prof. Christina CHAI
(NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore) |
|
| 14:00 | Active Site Inhibitors of Sphingosine 1-Phosphate Lyase - Exploring Novel Biology with Tool Compounds |
Dr Sven WEILER
(BASILEA PHARMACEUTICA INTERNATIONAL LTD., Basel, Switzerland) |
|
| 14:00 | Discovery of First-in Class, Selective and Noncovalent Small Molecule Inhibitors of DNMT1 |
Dr Allan JORDAN
(CANCER RESEARCH UK MANCHESTER INSTITUTE, Manchester, United Kingdom) |
|
| 14:20 | Identification of New Antimalarial GSK607: An Example of Adaptive and Differentiated Early Drug Development |
Dr Esther FERNANDEZ
(GLAXOSMITHKLINE, Tres Cantos, Spain) |
|
| 14:20 | Controlling Sphingosine-1-Phosphate Levels as a Therapeutic Strategy |
Dr Webster L. SANTOS
(VIRGINIA TECH, Blacksburg, United States) |
|
| 14:20 | ASTX660, the First Fragment-Derived IAP Antagonist in the Clinic |
Dr Steven HOWARD
(ASTEX THERAPEUTICS , Cambridge , United Kingdom) |
| 14:40 | IUPAC-Richter Prize Lecture
Discovery of CFTR Modulators For The Treatment of Cystic Fibrosis |
Dr Peter GROOTENHUIS
(VERTEX PHARMACEUTICALS, San Diego, United States) |
|
| 14:40 | Mechanisms of HIV-1 Nucleocapsid Protein Inhibition by Small Molecules Targeting RNA |
Dr Alice SOSIC
(UNIVERSITY OF PADOVA, Padova, Italy) |
|
|
|
| 15:00 | End of the Day |
|
| 15:30 | Excursions |
|
| 20:00 | Banquet |
|
| Cankarjev dom - Grand Reception Hall | | Thursday September 6, 2018 |
Session 20 'Technologies'
Recent Developments in Nucleoside Medicinal Chemistry | Session 21 'Therapeutic Areas'
Inflammatory and Autoimmune Diseases | Session 22 'Chemical Biology'
Enzyme Activators and Positive Allosteric Modulators |
| Marmorna Hall 1 | Kocka Hall | Marmorna Hall 2 |
| 08:30 | Session Chair |
Dr Jared CUMMING
(MSD, Boston, United States) |
|
| 08:30 | Session Chair |
Prof. Stanislav GOBEC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
|
| 08:30 | Session Chair |
Prof. Joachim MITTENDORF
(BAYER AG, Wuppertal, Germany) |
|
| 08:35 | Cyclic Dinucleotide STING Agonists as Anti-Tumor Agents |
Dr Wes TROTTER
(MSD, Boston, United States) |
|
| 08:35 | Nonpeptidic Selective Inhibitors of Immunoproteasome |
Prof. Stanislav GOBEC
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia) |
|
| 08:35 | Design, Synthesis, and Mechanism of β-Glucocerebrosidase Activators for Gaucher’s and Parkinson’s Diseases |
Prof. Richard B. SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, IL, United States) |
|
| 09:15 | Discovery of JNJ-64619178 as a Potent and Selective PRMT5 Inhibitor for the Treatment of Lung and Hematologic Cancers |
Dr Jan Willem THURING
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium) |
|
| 09:15 | Small Molecule Immunomodulators that Target Toll-Like Receptors |
Prof. Hang YIN
(TSINGHUA UNIVERSITY, Beijing, China) |
|
| 09:15 | Positive Allosteric Modulators of the GABA-B Receptor |
Dr Sean C. TURNER
(ABBVIE, Ludwigshafen am Rhein, Germany) |
|
| 09:35 | Design and Synthesis of Congerners of Cyclic ADP-Ribose, a Ca2+-Mobilizing Second Messenger, Toward Identification of the Target Protein |
Prof. Satoshi SHUTO
(HOKKAIDO UNIVERSITY, Sapporo, Japan) |
|
| 09:35 | A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Treat Non-Alcoholic Steatohepatitis
(EFMC-YMCS Presentation Prize) |
Dr Daniel MERK
(ETH ZÜRICH, Zürich, Switzerland) |
|
| 09:35 | The Value of Orthogonal Techniques for Elucidating Binding Site(s) of GPCR Allosteric Modulators: a Case Study With Positive Allosteric Modulators of Dopamine Receptors |
Dr Anne VALADE
(UCB, Braine-l'Alleud, Belgium) |
|
| 09:55 | Development of Novel Sialyltransferase Inhibitors via Computer Aided Drug Design |
Mr Andrew MONTGOMERY
(UNIVERSITY OF WOLLONGONG, Wollongong, Australia) |
|
| 09:55 | Discovery of SPL-707: A Potent, Selective, and Orally Bioavailable SPPL2a Inhibitor |
Dr Juraj VELCICKY
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
|
| 09:55 | AMPA Receptor Positive Allosteric Modulators Based on New Scaffolds: Design, Synthesis, and Studies |
Dr Vladimir A. PALYULIN
(LOMONOSOV MOSCOW STATE UNIVERSITY, Moscow, Russia) |
|
|
| 10:15 | Exhibition & Coffee (brunch) |
|
| Steklena & Kupola Hall |
Session 23 'Technologies'
PET Imaging as a Tool for in vivo Drug Evaluation and Development
(EANM Session) | Session 24
Late Breaking News | Session 25 'Therapeutic Areas'
Cardiometabolic Diseases |
| Marmorna Hall 1 | Kocka Hall | Marmorna Hall 2 |
| 10:45 | Session Chair |
Prof. Antony GEE
(KING'S COLLEGE LONDON, London, United Kingdom) |
|
| 10:45 | Session Chair |
Dr Anna KARAWAJCZYK
(SELVITA, Krakow, Poland) |
|
| 10:45 | Session Chair |
Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark) |
|
| 10:50 | PET Molecular Imaging – an Overview |
Prof. Antony GEE
(KING'S COLLEGE LONDON, London, United Kingdom) |
|
| 10:50 | First Disclosure of the Clinical Candidate BAY-840, a Potent And Selective hBradykinin B1 Antagonist for the Treatment of Chronic Inflammatory Diseases, Generated within the Bayer-Evotec Strategic Alliance |
Dr Stefan BÄURLE
(BAYER AG, Berlin, Germany) |
|
| 10:50 | C-Natruiretic Peptide Agonists for Cardiovascular Disease |
Prof. David SELWOOD
(UNIVERSITY COLLEGE LONDON, London, United Kingdom) |
|
| 11:30 | PET in Neuroscience Drug Discovery and Development |
Dr Magnus SCHOU
(KAROLINSKA INSTITUTE, Stockholm, Sweden) |
|
| 11:10 | Discovery of GDC-0077: A Highly Selective Inhibitor and Degrader of Mutant PI3K-Alpha |
Dr Jamie KNIGHT
(CHARLES RIVER, Harlow, United Kingdom) |
|
| 11:30 | The Discovery of Semaglutide - A Journey from Ala Scan to Structural Design of GLP-1 Analogues |
Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark) |
|
| 11:50 | PET for Oncology Drug Discovery and Development |
Prof. Bert WINDHORST
(VU UNIVERSITY MEDICAL CENTER, Amsterdam, The Netherlands) |
|
| 11:30 | Anti-HBV Drug Discovery Enabled by Structure-Based Drug Design and Phenotypic Screening |
Dr Hong SHEN
(ROCHE INNOVATION CENTER, Shanghai, China) |
|
| 11:50 | Discovery and Optimization of Non-Covalent, Selective, and Bioavailable Small Molecule Inhibitors of the KEAP1-Nrf2 Pathway |
Dr Hauke SZILLAT
(SANOFI, Frankfurt, Germany) |
|
| 12:10 | Discovery of Candidates for PET Molecular Imaging of Pathological TDP-43 Aggregates in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Patients |
Dr Vincent DARMENCY
(AC IMMUNE SA, Lausanne, Switzerland) |
|
| 11:50 | Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 that Enables Transient Target Engagement for the Treatment of Haematological Malignancies |
Dr Bernard BARLAAM
(ASTRAZENECA, Cambridge, United Kingdom) |
|
| 12:10 | Discovery and Clinical Evaluation of MK-8150, a Novel Nitric Oxide Donor with a Unique Mechanism of Nitric Oxide Release |
Dr Amjad ALI
(MERCK & CO. INC., Kenilworth, United States) |
| |
|
| 12:10 | The Discovery of CNP520, an Amino-1,4-Oxazine BACE Inhibitor in Prevention Studies |
Dr Rainer MACHAUER
(NOVARTIS PHARMA AG, Basel, Switzerland) |
|
|
|
| 12:30 | Chair |
Dr Cornelia ZUMBRUNN
(IDORSIA PHARMACEUTICALS, Allschwil, Switzerland) |
| Kocka Hall |
| Smart Chemical Probes: from Bromodomain Ligands to Natural Products |
Prof. Cristina NEVADO
(UNIVERSITY OF ZURICH, Zurich, Switzerland) |
| Kocka Hall |
| 13:15 | Closing Remarks, Poster Prizes and Welcome to EFMC-ISMC 2020 |
Prof. Marko ANDERLUH (UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| Kocka Hall |
|
